Table 1.
Clinical and genetic features and subsequent events in 51 patients with CMML.
| Variable | CMML (n = 51) |
CMML-1 (n = 34) |
CMML-2 (n = 17) |
p-Value |
|---|---|---|---|---|
| Age in years; median (range) | 71 (35–88) | 73 (35–88) | 66 (53–80) | 0.0647 |
| Male; n (%) | 36 (71) | 25 (74) | 11 (65) | 0.532 |
| Other malignancies; n (%) a | 20 (39) | 14 (41) | 6 (35) | 0.7672 |
| Leukemic transformations; n (% LT) | 14 (28) | 4 (12) | 10 (59) | 0.0008 |
| Overall survival; median months | 42 | 129 | 29 | 0.0077 |
| Genetic Analysis |
CMML
(n = 36) |
CMML-1
(n = 23) |
CMML-2
(n = 13) |
AML
(n = 14) |
| Epigenetic regulation analysis; n (%) | ||||
| TET2 | 16 (44) | 12 (52) | 4 (31) | 3 (21) |
| ASXL1 | 15 (42) | 8 (35) | 7 (54) | 8 (57) |
| DNMT3A | 5 (14) | 2 (9) | 3 (23) | 2 (14) |
| BCOR | 2 (6) | 0 (0) | 2 (15) | 2 (14) |
| EZH2 | 1 (3) | 1 (4) | 0 (0) | 0 (0) |
| Spliceosome mutational analysis; n (%) | ||||
| SRSF2 | 10 (28) | 6 (26) | 4 (31) | 4 (29) |
| ZRSR2 | 7 (19) | 5 (22) | 2 (15) | 2 (14) |
| U2AF1 | 1 (3) | 1 (4) | 0 (0) | 0 (0) |
| Cellular signaling analysis; n (%) | ||||
| NRAS | 5 (14) | 2 (9) | 3 (23) | 4 (29) |
| KRAS | 3 (8) | 1 (4) | 2 (15) | 2 (14) |
| CBL | 1 (3) | 1 (4) | 0 (0) | 0 (0) |
| FLT3 | 2 (6) | 0 (0) | 2 (15) | 1 (7) |
| PTPN11 | 2 (6) | 1 (4) | 1 (8) | 2 (14) |
| Other; n (%) | ||||
| RUNX1 | 12 (33) | 7 (30) | 5 (38) | 6 (43) |
| SETBP1 | 2 (6) | 0 (0) | 2 (15) | 2 (14) |
| NPM1 | 3 (8) | 1 (4) | 2 (15) | 2 (14) |
a Patients with other cancers: prostate cancer (3), breast cancer (3), non-Hodgkin lymphoma (2), multiple cancers (2), and treatment-related cancers (2). Note on treatment: no treatment (11 patients), hydroxyurea (11 patients), decitabine (12 patients), azacitidine (11 patients), venetoclax with demethylating agents (2 patients), and various other protocols (4 patients). Special cases include 2 patients with treatment-related CMML and 5 who underwent allogeneic transplantation.